Navigation Links
Jennerex and Transgene Announce Presentation of Phase 1 Data Demonstrating that JX-594 Administration Targets Tumor Vasculature
Date:4/5/2011

SAN FRANCISCO and ILLKIRCH, France, April 6, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, reported interim results from Phase 1 dose-escalation clinical trials demonstrating that administration of JX-594 targets tumor vasculature. By directly targeting and replicating within tumor vasculature, JX-594 disrupts the blood supply to the solid tumors contributing to destruction of the cancer. Data were reported in a poster presentation at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) in Orlando, Florida.

"In addition to targeting, infecting and destroying cancer cells and stimulating a targeted immune response against remaining cancer cells, the analysis presented at AACR demonstrates JX-594's critical third mechanism of action—the disruption of the blood supply to the tumor," said David H. Kirn, M.D., president and chief executive officer of Jennerex.  

"Importantly, these data show that both intravenous and intratumoral injection of JX-594 can effectively attack tumor vasculature. These results further demonstrate that JX-594 may have therapeutic benefit for a variety of solid tumors including liver, colorectal and other cancers," added Philippe Archinard, chairman and chief executive officer of Transgene.

Twenty three patients were enrolled in the Phase 1 dose-escalation clinical study using intravenous JX-594 to treat advanced, treatment refractory solid tumors. Tumor biopsies, evaluated through immunohistochemical analysis, showed that JX-594 given intravenously infected the vasculature of tumors causing the blood supply to the tumor to be disrupted. In addition, in another trial of patients with primary liver can
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients With Liver Tumors
2. Jennerex Names Ursula Fritsch, PharmD, as Vice President, Regulatory Affairs
3. Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer
4. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
5. Jennerex Appoints Lara Longpre to Chief Operating Officer
6. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
7. Jennerex Announces Presentations at Upcoming Conferences
8. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
9. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
10. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
11. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... --  Ventana Medical Systems, Inc.  (Ventana), a member of ... an agreement with Merck KGaA, Darmstadt, Germany ... the United States and ... division on the development and commercialization of a companion ... diagnostic assays. In alignment with Merck KGaA,s strategic approach ...
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) ... November 30, 2013, compared to sales of $2,202,000 for the ... again, this quarter has also shown growth over the preceding ... quarter of this fiscal year. Markets that experienced sales increases ...
(Date:1/15/2014)... today announced it has established a relief fund ... that has gripped much of the nation. AARP and its ... support these emergency relief efforts AARP and AARP Foundation will ... to $500,000 in aid. The matching program will be administered ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
... Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced ... its strategic advisor as it pursues various avenues aimed at ... ANA598, in development for the treatment of hepatitis C.  Anadys ... conclusion of 12 weeks of dosing ANA598 in combination with ...
... Inc. (OTC Bulletin Board: HEWA), a leading retail mail-order ... (VIPPS(CM)) accreditation from The National Association of Boards of Pharmacy (NABP). ... accredited in the United States .   , ... According to NABP which has ...
Cached Medicine Technology:Anadys Retains Lazard as Strategic Advisor 2Anadys Retains Lazard as Strategic Advisor 3Anadys Retains Lazard as Strategic Advisor 4Anadys Retains Lazard as Strategic Advisor 5HealthWarehouse.com Receives VIPPS Accreditation From The National Association of Boards of Pharmacy 2
(Date:7/10/2014)... In his latest blog post at ... facility CEO Per Wickstrom has listed 5 ways to ... confirm an appointment, get information or sometimes even just ... being annoying is a skill that most people don’t ... to keep the dialogue moving without coming across as ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 A ... program that gets clients off to a great start ... can believe in, has launched a new Eating Disorders ... The new section highlights:, , Different ... Statistic Manual of Mental Disorders (DSM-IV), including anorexia nervosa, ...
(Date:7/10/2014)... City, CA (PRWEB) July 10, 2014 ... announced the latest results of the 4th “Trending ... "Source-to-Pay” suite model. , Every day multinational ... data, contracts, expense forms etc. To meet this ... "Source-to-Pay" (S2P) suites which can be defined as ...
(Date:7/10/2014)... widespread across the United States, due in large to ... of clinical data that will become available for research ... experts in healthcare have become increasingly focused on clinical ... purpose of gleaning insights that have the potential to ... that is known as big data. ...
(Date:7/10/2014)... professional football players who have shoulder stabilization surgery are ... finds. Shoulder instability is a common injury among ... to fix the problem has been unclear, the study ... who had shoulder stabilization surgery. Ninety percent of those ... as playing in at least one regular season game. ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 3Health News:Six cases where big data can reduce healthcare costs 2Health News:Six cases where big data can reduce healthcare costs 3Health News:Six cases where big data can reduce healthcare costs 4Health News:Shoulder Surgery Gets NFL Players Back in the Game 2
... came to the Brampton, Ont., Tim Horton's location are being ... ,According to health officials in Peel Region, an employee ... tested positive for hepatitis A. ,Peel's associate medical ... that the risk of transmission is low. ,However De Villa ...
... Egger, of the University of Bern in Switzerland, AIDS ... side effects// due the drug. ,There is ... It been ten years since the antiretroviral (ARVs) have ... and drawbacks. Scientists say that the combinations of drugs ...
... fibers could stretch to three times its length before going ... to six times// their original length before breaking. ... from a soluble protein, fibrinogen. When an injury occurs ... a mesh, which dries and hardens, so that bleeding stops. ...
... been a storm brewing over a particular brand of milk, ... on the warfarin drug. Fonterra, the company// that is manufacturing ... were well aware of the impending risks of the milk ... to disclose the warning on the product. ...
... who was denied admission to a medical college here because ... disability, has urged President// A.P.J. Abdul Kalam to intervene. ... of the state joint entrance examination, was denied admission to ... examining her again despite the chief district medical officer R.C. ...
... popular supermarket chains have announced that they would completely avoid ... ,Trans fat was recently in the news as it increased ... thought to cause cancers among some people. The supermarket chains ... amounts of hydrogenated oil pose great threat and affected the ...
Cached Medicine News:
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: